From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Clinical data
AHFS/ International Drug Names
Routes of
By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
CAS Number
PubChem CID
ECHA InfoCard 100.067.468 Edit this at Wikidata
Chemical and physical data
Formula C11H14N4O4
Molar mass 266.25 g/mol
3D model (JSmol)

Doxofylline (also known as doxophylline) is a xanthine derivative drug used in the treatment of asthma.[1]

Medical uses[edit]

It has antitussive[citation needed] and bronchodilator[2] effects, and acts as a phosphodiesterase inhibitor.[3]

In animal and human studies, it has shown similar efficacy to theophylline but with significantly fewer side effects.[4]


Unlike other xanthines, doxofylline lacks any significant affinity for adenosine receptors and does not produce stimulant effects. This suggests that its antiasthmatic effects are mediated by another mechanism, perhaps its actions on phosphodiesterase.[1]


It is marketed under many brand names worldwide, including: Xiva, An Li Nuo Er, An Sai Ma, Ansimar, Asima, Bestofyline, Chuan Ning, D-Fyal, Dilatair, Doxiba, Doxobid, Doxobron, Doxofilina, Doxofillina, Doxofyllin, Doxoll, Doxophylline, Doxovent, Doxyjohn, Fei Te Ai Si, Jian Fang Neng, Lang Ming, Lv Meng, Mai Ping Xi, Maxivent, Mucosma, Na De Lai, Phylex, Phyllin, Puroxan, Rexipin, Shu Zhi, Shuai An, Shuweixin, Suo Di, Suo Ji, Suo Li An, Xi Si Nuo, Xin Qian Ping, Xin Xi Ping, Yi Suo, and Yili.[5]

It is also marketed as a combination drug with terbutaline as Doxoll-TL, Mucosma-T and Phylex-TR.[5]

It is also marketed as a combination drug with montelukast as Doxoll-ML, Doxomont, Doxoril-M, Doxovent-M, Lunair-M, and Venidox-M.[5]


  1. ^ a b Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Arch Int Pharmacodyn Ther. 295: 221–37. PMID 3245738. 
  2. ^ Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671. 
  3. ^ Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Curr Med Res Opin. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710. 
  4. ^ Sankar J, Lodha R, Kabra SK (March 2008). "Doxofylline: The next generation methylxanthine". Indian J Pediatr. 75 (3): 251–4. doi:10.1007/s12098-008-0054-1. PMID 18376093. 
  5. ^ a b c "Doxofylline - international brand names". Retrieved 18 January 2017. 

Further reading[edit]

  • Shukla, Dali; Chakraborty, Subhashis; Singh, Sanjay; Mishra, Brahmeshwar (2009). "Doxofylline: A promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease". Expert Opinion on Pharmacotherapy. 10 (14): 2343. doi:10.1517/14656560903200667. PMID 19678793.